Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2392-2397

  Ghatnekar, Ola ^a   Andersson, Roland ^b,c   Svensson, Marianne ^a   Persson, Ulf ^a   Ringdahl, Ulrika ^c   Zeilon, Paula ^c   Borrebaeck, Carl A K ^c  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

cost utility; early diagnosis; health economics; pancreatic cancer; proteomics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEOMICS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

COST UTILITY; EARLY DIAGNOSIS; HEALTH ECONOMICS; PANCREATIC CANCER; PROTEOMICS;

AGED; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; PANCREATIC NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883776306     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28256     Document Type: Article

References (28)

1. Polanski M, Anderson NL,. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007; 1: 1-48.
2. Borrebaeck CA, Wingren C,. Transferring proteomic discoveries into clinical practice. Expert Rev Proteomics 2009; 6: 11-3.
3. Hanash SM, Pitteri SJ, Faca VM,. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452: 571-9.
4. Ingvarsson J, Wingren C, Carlsson A, et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 2008; 8: 2211-9.
5. Sculpher M, Fenwick E, Claxton K,. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000; 17: 461-77.
6. Annemans L, Geneste B, Jolain B,. Early modelling for assessing health and economic outcomes of drug therapy. Value Health 2000; 3: 427-34.
7. Claxton K,. Oft, Vbp: Qed? Health Econ 2007; 16: 545-58.
8. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251-4.
9. Persson U, Svensson J, Pettersson B,. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 2012; 10: 217-25.
10. Wingren C, Sandstrom A, Segersvard R, et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 2012; 72: 2481-90.
11. Sharma C, Eltawil KM, Renfrew PD, et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17: 867-97.
12. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
13. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7.
14. Weinstein MC, Torrance G, McGuire A,. QALYs: the basics. Value Health 2009; 12 Suppl 1:S 5-9.
15. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007; 110: 738-44.
16. Burstrom K, Johannesson M, Diderichsen F,. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006; 76: 359-70.
17. Ljungman D, Lundholm K, Hyltander A,. Cost-utility estimation of surgical treatment of pancreatic carcinoma aimed at cure. World J Surg 2011; 35: 662-70.
18. Muller-Nordhorn J, Roll S, Bohmig M, et al. Health-related quality of life in patients with pancreatic cancer. Digestion 2006; 74: 118-25.
19. Tingstedt B, Andersson E, Flink A, et al. Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach. World J Surg 2011; 35: 2298-305.
20. National Board of Health and Welfare, Nationella riktlinjer för bröst-, kolorektal- och prostatacancer: Beslutsstöd för prioriteringar, 2007.
21. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134: 95-101.
22. Fenwick E, O'Brien BJ, Briggs A,. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-15.
23. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-54.
24. National Board of Health and Welfare. Swedish Health and Welfare Statistical Databases, Cancer statistics 2010.
25. Tingstedt B, Weitkämper C, Andersson R,. Early Onset Pancreatic Cancer-comparison against matched controls. Annals of Gastroenterology 2011; 24: 206-12.
26. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-80.
27. Larghi A, Verna EC, Lecca PG, et al. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009; 15: 1907-14.
28. Greenhalf W, Grocock C, Harcus M, et al. Screening of high-risk families for pancreatic cancer. Pancreatology 2009; 9: 215-22.